TITLE:
Phase I/II Study of Curdlan Sulfate

CONDITION:
HIV Infections

INTERVENTION:
Curdlan sulfate

SUMMARY:

      To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in
      HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single
      doses and then, after FDA review, daily doses for 7 days.
    

DETAILED DESCRIPTION:

      In Phase I of the study, escalating single doses of intravenous curdlan sulfate are tested.
      In Phase II, curdlan sulfate is administered daily for 7 days. (NOTE: Phase I is completed.)
    

ELIGIBILITY:
Gender: All
Age: 18 Years to 60 Years
Criteria:

        Inclusion Criteria

        Patients must have:

          -  HIV seropositivity.

          -  No current AIDS-defining opportunistic infection, lymphoma, Kaposi's sarcoma, or
             other malignancy.

          -  CD4 count < 500 cells/mm3.

          -  No critical illness that would shorten life expectancy to < 16 weeks.

        Exclusion Criteria

        Concurrent Medication:

        Excluded:

          -  Antiretroviral or other experimental therapies.

          -  Anticoagulants.

          -  Steroids.

          -  Cytotoxic or immunosuppressive agents.

        Concurrent Treatment:

        Excluded:

          -  Radiotherapy.

        Patients with the following prior condition are excluded:

        History of heparin sensitivity.

        Prior Medication:

        Excluded within 1 month prior to study entry:

          -  Antiretroviral or other experimental therapies.

          -  Anticoagulants.

          -  Steroids.

          -  Cytotoxic or immunosuppressive agents.

        Prior Treatment:

        Excluded:

          -  Radiotherapy within 1 month prior to study entry. Active IV drug abuse.
      
